European Annals of Allergy and Clinical Immunology THE OFFICIAL JOURNAL OF AAITO THE OFFICIAL JOURNAL OF SPAIC HOME PAGE

EDITORS IN CHIEF
L. Cecchi (Firenze - Italy)

P. Carreiro-Martins (Lisbon - Portugal)

 

HONORARY EDITOR
A. Sabbah (Angers - France)

 

ASSOCIATE EDITORS
R. Rodrigues Alves (Lisbon - Portugal)
A. Tedeschi (Milano - Italy)

 

EDITORIAL BOARD
M. Morais-Almeida (Lisbon - Portugal)
R. Asero (Milan - Italy)
M.B. Bilò (Ancona - Italy)
F. Bonifazi (Ancona - Italy)
L.M. Borrego (Lisbon - Portugal)

K. Brockow (München - Germany)
A.À. Cruz (Salvador - Brasil)
L. Delgado (Oporto - Portugal)
P. Demoly (Montpellier - France)
G. D'Amato (Napoli - Italy)
M. Drouet (Angers - France)
M. Fernandez-Rivas (Madrid - Spain)
A. Fiocchi (Milano - Italy)

J. Fonseca (Oporto - Portugal)
D. Macchia (Firenze - Italy)
F. Mastrandrea (Taranto - Italy)
M. Maurer (Berlin - Germany)
G. Moscato (Pavia - Italy)
A. Musarra (Reggio Calabria - Italy)
C. Nunes (Portimao - Portugal)
M. Olivieri (Verona - Italy)
P. Parronchi (Firenze - Italy)
G. Passalacqua (Genova - Italy)
G. Pauli (Strasbourg - France)
E. Pedro (Lisbon - Portugal)
A. Perino (Torino - Italy)
L.K. Poulsen (Copenaghen - Denmark)
O. Quercia (Faenza - Italy)
A. Romano (Roma - Italy)
E. Scala (Roma - Italy)
D. Solé (Sao Paulo - Brasil)
A. Todo Bom (Coimbra - Portugal)
S. Voltolini (Genova - Italy)

 

SCIENTIFIC COMMITTEE
L. Antonicelli (Italy)
A. Bener (Turkey)
H. Bazin (Belgium)
J. Bellanti (USA)
C. Geller-Bernstein (Israel)
M. Cugno (Italy)
B. David (France)
S. Durham (UK)
G.P. Girolomoni (Italy)
R. Jarish (Austria)
S.G.O. Johansson (Sweden)
F. Levi-Shaffer (Israel)
H. Lowenstein (Denmark)
J.L. Malo (Canada)
A.G. Palma-Carlos (Portugal)
G. Scadding (UK)
G. Scadding (UK)
E. Stevens (Belgium)
R. van Ree (Netherlands)

 

FOUNDER AND CORRESPONDING MEMBER
G.M. Halpern (USA)


*************************

Editors in Chief
Lorenzo Cecchi
Pedro Carreiro-Martins

Chief Business & Content Officer
Ludovico Baldessin

Publishing Editor

Greta Schincaglia

g.schincaglia@lswr.it
Ph. 0039 (0)2-88184.512


Production Manager

Walter Castiglione
w.castiglione@lswr.it
Ph. 0039 (0)2-88184.222

Sales
Stefano Busconi
dircom@lswr.it
Ph. 0039 (0)2-88184.404

Printing
Mccgraphics
Pol. Ind. Txirrita Maleo Pab 11
20100 Errenteria (Gipuzkoa), Spain

EDRA SpA
Via G. Spadolini, 7
20141 Milano - Italy
Ph. 0039 (0)2-88184.1
Fax 0039 (0)2-88184.301 
www.edizioniedra.it

Contents »

Subcutaneous immunotherapy with aeroallergens - Evaluation of adherence in real life


T. Lourenço1tatiana-lourenco@live.com.ptM. Fernandes1,2, C. Coutinho1 A. Lopes1, A. Spínola Santos1, M. Neto1, M. Pereira Barbosa1,3

Show more: Authors information and Publication history

Doi
https://doi.org/10.23822/EurAnnACI.1764-1489.122
 
Summary
Introduction. Adherence in allergen immunotherapy is crucial for its efficacy. At least 3 years of treatment are recommended for achieving a long-term modifying effect. Objectives. To assess patient's adherence and to identify determinant factors for allergen subcutaneous immunotherapy (SCIT) suspension in patients with respiratory allergy. Methods.  Retrospective analysis of the medical record of patients submitted to SCIT between January 2013 and December 2016 in our Department. Results. 323 patients were included: 52% female; mean age 30±13 years; average treatment time 19±13 months. 52 patients (16%) stopped SCIT: 54% female; mean age 30±9 years; average treatment time 12±6 months; 67% dropped the treatment during the 1st year, 27% in the 2nd and 6% during the 3rd year of treatment. Adherence rate determined was 77%.  The most frequent reasons for withdrawal were due to economic reasons (47.9%), followed by patients' perception of no clinical improvement (23%) and change to sublingual immunotherapy (11.6%). Conclusion. Adherence rate in our study was 77%. Economic reasons were the main cause of abandonment in the first year, while the perception of non-improvement was the main reason for abandonment in subsequent years. Adequate information on SCIT prescribing and rigorous monitoring of patients during the treatment can improve adherence.   

Key words    
allergy; allergic respiratory diseases; allergen immunotherapy; subcutaneous immunotherapy; adherence

FULL TEXT